{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T12:29:06Z","timestamp":1769084946551,"version":"3.49.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s12325-016-0337-2","type":"journal-article","created":{"date-parts":[[2016,5,4]],"date-time":"2016-05-04T09:29:22Z","timestamp":1462354162000},"page":"862-875","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Renal Function in Nucleos(t)ide Analog-Treated Patients With Chronic Hepatitis B: A Systematic Literature Review and Network Meta-Analysis"],"prefix":"10.1007","volume":"33","author":[{"given":"Henry L. Y.","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javed","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subhajit","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamal","family":"Hamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,4]]},"reference":[{"key":"337_CR1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","volume":"57","author":"European Association for the Study of the Liver","year":"2012","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167\u201385.","journal-title":"J Hepatol"},{"key":"337_CR2","unstructured":"WHO fact sheet on Hepatitis B. 2015. http:\/\/www.who.int\/mediacentre\/factsheets\/fs204\/en\/ . Accessed Apr 18, 2016."},{"key":"337_CR3","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0140-6736(71)92572-4","volume":"2","author":"B Combes","year":"1971","unstructured":"Combes B, Shorey J, Barrera A, et al. Glomerulonephritis with deposition of Australia antigen-antibody complexes in glomerular basement membrane. Lancet. 1971;2:234\u20137.","journal-title":"Lancet"},{"key":"337_CR4","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1136\/pgmj.2009.092775","volume":"86","author":"EC Chacko","year":"2010","unstructured":"Chacko EC, Surrun SK, Mubarack Sani TP, Pappachan JM. Chronic viral hepatitis and chronic kidney disease. Postgrad Med J. 2010;86:486\u201392.","journal-title":"Postgrad Med J"},{"key":"337_CR5","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000077065","volume":"24","author":"R Bhimma","year":"2004","unstructured":"Bhimma R, Coovadia HM. Hepatitis B virus-associated nephropathy. Am J Nephrol. 2004;24:198\u2013211.","journal-title":"Am J Nephrol"},{"key":"337_CR6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S1665-2681(19)31565-0","volume":"10","author":"Z Yi","year":"2011","unstructured":"Yi Z, Jie YW, Nan Z. The efficacy of anti-viral therapy on hepatitis B virus-associated glomerulonephritis: a systematic review and meta-analysis. Ann Hepatol. 2011;10:165\u201373.","journal-title":"Ann Hepatol"},{"key":"337_CR7","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJM199105233242103","volume":"324","author":"KN Lai","year":"1991","unstructured":"Lai KN, Li PK, Lui SF, et al. Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med. 1991;324:1457\u201363.","journal-title":"N Engl J Med"},{"key":"337_CR8","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3949\/ccjm.74.5.353","volume":"74","author":"G Appel","year":"2007","unstructured":"Appel G. Viral infections and the kidney: HIV, hepatitis B, and hepatitis C. Cleve Clin J Med. 2007;74:353\u201360.","journal-title":"Cleve Clin J Med"},{"issue":"Suppl","key":"337_CR9","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1002\/hep.22885","volume":"49","author":"RJ Fontana","year":"2009","unstructured":"Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology. 2009;49(Suppl):S185\u201395.","journal-title":"Hepatology"},{"key":"337_CR10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1155\/2015\/596829","volume":"2015","author":"G Deray","year":"2015","unstructured":"Deray G, Buti M, Gane E, et al. Hepatitis B virus infection and the kidney: renal abnormalities in HBV patients, antiviral drugs handling, and specific follow-up. Adv Hepatol. 2015;2015:11. doi: 10.1155\/2015\/596829 (article ID 596829).","journal-title":"Adv Hepatol."},{"key":"337_CR11","doi-asserted-by":"crossref","unstructured":"Deterding K, Lampe N, Reijnders J, et al. Prevalence and severity of kidney dysfunction in patients with chronic hepatitis B in Europe: data from the European VIRGIL cohort. In: Abstracts of the 46th Annual Meeting of the European Association for the Study of the Liver. Berlin: European Association for the Study of Liver; 2011. Abstract number 366.","DOI":"10.1016\/S0168-8278(11)60368-1"},{"key":"337_CR12","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.jhep.2011.03.030","volume":"55","author":"S Mauss","year":"2011","unstructured":"Mauss S, Berger F, Filmann N, et al. Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. J Hepatol. 2011;55:1235\u201340.","journal-title":"J Hepatol"},{"key":"337_CR13","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1440-1746.2011.06852.x","volume":"27","author":"YJ Kim","year":"2012","unstructured":"Kim YJ, Cho HC, Sinn DH, et al. Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients. J Gastroenterol Hepatol. 2012;27:306\u201312.","journal-title":"J Gastroenterol Hepatol"},{"key":"337_CR14","unstructured":"Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. http:\/\/www.handbook.cochrane.org . Accessed Apr 18, 2016"},{"key":"337_CR15","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. http:\/\/www.nice.org.uk\/article\/pmg9\/resources\/non-guidance-guide-to-the-methods-of-technology-appraisal-2013-pdf . Accessed Apr 18, 2016."},{"key":"337_CR16","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264\u20139.","journal-title":"Ann Intern Med"},{"key":"337_CR17","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/jech.52.6.377","volume":"52","author":"SH Downs","year":"1998","unstructured":"Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52:377\u201384.","journal-title":"J Epidemiol Community Health"},{"key":"337_CR18","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","volume":"14","author":"DC Hoaglin","year":"2011","unstructured":"Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health. 2011;14:429\u201337.","journal-title":"Value Health"},{"key":"337_CR19","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/0272989X12458724","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Mak. 2013;33:607\u201317.","journal-title":"Med Decis Mak"},{"key":"337_CR20","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/0272989X12455847","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Mak. 2013;33:641\u201356.","journal-title":"Med Decis Mak"},{"key":"337_CR21","first-page":"S185","volume":"7","author":"R Rooprai","year":"2013","unstructured":"Rooprai R, Nijhawan S. Comparative evaluation of renal function in patients of chronic hepatitis B treated with nucleos(t)ide analogues. Hepatol Int. 2013;7:S185.","journal-title":"Hepatol Int."},{"key":"337_CR22","first-page":"S191","volume":"7","author":"E Esaulenko","year":"2013","unstructured":"Esaulenko E, Stukov BV, Nikitina OE. Evaluation of patient characteristics and efficacy with entecavir and telbivudine treatment in Russian patients with chronic hepatitis B. Hepatol Int. 2013;7:S191.","journal-title":"Hepatol Int"},{"key":"337_CR23","first-page":"1104A","volume":"60","author":"Z Krastev","year":"2014","unstructured":"Krastev Z, Kotzev IA, Celen MK, McNeeley D, Hamed KA. Efficacy and safety of telbivudine versus tenofovir treatment based on the Roadmap concept: results from a randomized, controlled trial in HBeAg-negative chronic hepatitis B patients. Hepatology. 2014;60:1104A.","journal-title":"Hepatology"},{"key":"337_CR24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.cgh.2013.09.032","volume":"12","author":"H Park","year":"2014","unstructured":"Park H, Park JY, Kim SU, et al. A prospective randomized trial of switching to telbivudine plus adefovir in HBeAg-positive lamivudine-resistant chronic hepatitis B patients who have suboptimal response to lamivudine plus adefovir. Clin Gastroenterol Hepatol. 2014;12:157.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"337_CR25","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1523-1755.2004.00866.x","volume":"66","author":"H Izzedine","year":"2004","unstructured":"Izzedine H, Hulot JS, Launay-Vacher V, et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int. 2004;66:1153\u20138.","journal-title":"Kidney Int"},{"key":"337_CR26","doi-asserted-by":"crossref","first-page":"776","DOI":"10.5009\/gnl14297","volume":"9","author":"S Lee","year":"2015","unstructured":"Lee S, Park JY, Song K, et al. Comparison of the effects of telbivudine and entecavir treatment on estimated glomerular filtration rate in patients with chronic hepatitis B. Gut Liver. 2015;9:776\u201383.","journal-title":"Gut Liver."},{"key":"337_CR27","doi-asserted-by":"crossref","first-page":"1118A","DOI":"10.1016\/j.jhep.2014.01.020","volume":"60","author":"CH Hung","year":"2014","unstructured":"Hung CH, Chen CH, Lu SN, Hu TH, Wang JH, Lee CM. Tenofovir versus entecavir in the treatment of chronic hepatitis B with severe acute exacerbation. Hepatology. 2014;60:1118A.","journal-title":"Hepatology"},{"key":"337_CR28","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/hep.23044","volume":"50","author":"NB Ha","year":"2009","unstructured":"Ha NB, Ha NB, Garcia RT, et al. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology. 2009;50:727\u201334.","journal-title":"Hepatology"},{"key":"337_CR29","first-page":"S222","volume":"7","author":"PY Su","year":"2013","unstructured":"Su PY, Yen HH, Hsu YC, Wu SS, Su WW, Soon MS. Renal function for chronic hepatitis B patients treated with nucleoside antivirals\u2014a retrospective study in a medical center. Hepatol Int. 2013;7:S222.","journal-title":"Hepatol Int"},{"key":"337_CR30","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1365-2893.2012.01600.x","volume":"19","author":"HLY Chan","year":"2012","unstructured":"Chan HLY, Chen YC, Gane EJ, et al. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naive patients with HBV-related decompensated cirrhosis. J Viral Hepat. 2012;19:732\u201343.","journal-title":"J Viral Hepat"},{"issue":"138\u201346","key":"337_CR31","first-page":"e5","volume":"146","author":"EJ Gane","year":"2014","unstructured":"Gane EJ, Deray G, Liaw YF, et al. Telbivudine improves renal function in patients with chronic hepatitis b. Gastroenterology. 2014;146(138\u201346):e5.","journal-title":"Gastroenterology"},{"key":"337_CR32","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/apt.13036","volume":"41","author":"S Koklu","year":"2015","unstructured":"Koklu S, Gulsen MT, Tuna Y, et al. Differences in nephrotoxicity risk and renal effects among anti-viral therapies against hepatitis B. Aliment Pharmacol Ther. 2015;41:310\u20139.","journal-title":"Aliment Pharmacol Ther"},{"key":"337_CR33","first-page":"S186","volume":"1","author":"TH Hu","year":"2015","unstructured":"Hu TH, Chang KC, Tseng PL, Lin MT, Hung CH, Yen YH. A comparison of renal safety of telbivudine entecavir and tenofovir treatment in chronic hepatitis B patients: a single center large \u201creal life\u201d cohort study. Hepatol Int. 2015;1:S186.","journal-title":"Hepatol Int"},{"key":"337_CR34","doi-asserted-by":"crossref","first-page":"e54279","DOI":"10.1371\/journal.pone.0054279","volume":"8","author":"T Piratvisuth","year":"2013","unstructured":"Piratvisuth T, Komolmit P, Tanwandee T, et al. 52-Week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B. PLoS One. 2013;8:e54279.","journal-title":"PLoS One"},{"key":"337_CR35","first-page":"S69","volume":"1","author":"H Sun","year":"2014","unstructured":"Sun H, Zhang S, Wang M. Efficacy and safety of three different treatments in 183 patients with hepatitis B cirrhosis. Hepatol Int. 2014;1:S69.","journal-title":"Hepatol Int"},{"key":"337_CR36","doi-asserted-by":"crossref","first-page":"O90","DOI":"10.1111\/1469-0691.12220","volume":"20","author":"MC Tsai","year":"2014","unstructured":"Tsai MC, Chen CH, Hung CH, et al. A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study. Clin Microbiol Infect. 2014;20:O90\u2013100.","journal-title":"Clin Microbiol Infect"},{"key":"337_CR37","first-page":"S154","volume":"1","author":"MC Tsai","year":"2014","unstructured":"Tsai MC, Hung CH, Chen CH, et al. Comparing the change of renal function of tenofovir and telbivudine naive chronic hepatitis B patients. Hepatol Int. 2014;1:S154.","journal-title":"Hepatol Int"},{"issue":"95","key":"337_CR38","first-page":"e1","volume":"22","author":"MC Tsai","year":"2016","unstructured":"Tsai MC, Chen CH, Tseng PL, et al. Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience. Clin Microbiol Infect. 2016;22(95):e1\u20137.","journal-title":"Clin Microbiol Infect."},{"key":"337_CR39","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/s10620-014-3363-4","volume":"60","author":"C Tien","year":"2015","unstructured":"Tien C, Xu JJ, Chan LS, et al. Long-term treatment with tenofovir in Asian-American chronic hepatitis B patients is associated with abnormal renal phosphate handling. Dig Dis Sci. 2015;60:566\u201372.","journal-title":"Dig Dis Sci"},{"key":"337_CR40","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/jvh.12229","volume":"22","author":"X Qi","year":"2015","unstructured":"Qi X, Wang JY, Mao RC, Zhang JM. Impact of nucleos(t)ide analogues on the estimated glomerular filtration rate in patients with chronic hepatitis B: a prospective cohort study in China. J Viral Hepat. 2015;22:46\u201354.","journal-title":"J Viral Hepat"},{"key":"337_CR41","doi-asserted-by":"crossref","first-page":"e15074","DOI":"10.5812\/hepatmon.15074","volume":"14","author":"KH Liang","year":"2014","unstructured":"Liang KH, Chen YC, Hsu CW, Chang ML, Yeh CT. Decrease of serum angiotensin converting enzyme levels upon telbivudine treatment for chronic hepatitis B virus infection and negative correlations between the enzyme levels and estimated glomerular filtration rates. Hepat Mon. 2014;14:e15074.","journal-title":"Hepat Mon"},{"key":"337_CR42","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa021812","volume":"348","author":"SJ Hadziyannis","year":"2003","unstructured":"Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003;348:800\u20137.","journal-title":"N Engl J Med"},{"key":"337_CR43","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2011.11.030","volume":"57","author":"G Papatheodoridis","year":"2012","unstructured":"Papatheodoridis G, Buti M, Cornberg M, et al. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167\u201385.","journal-title":"J Hepatol"},{"key":"337_CR44","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1111\/jvh.12025","volume":"20","author":"Y Wang","year":"2013","unstructured":"Wang Y, Thongsawat S, Gane EJ, et al. Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. J Viral Hepat. 2013;20:e37\u201346.","journal-title":"J Viral Hepat"},{"key":"337_CR45","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3892\/br.2015.415","volume":"3","author":"Q Yang","year":"2015","unstructured":"Yang Q, Shi YU, Yang Y, Lou G, Lv F. Association between adefovir dipivoxil treatment and the risk of renal insufficiency in patients with chronic hepatitis B: a meta-analysis. Biomed Rep. 2015;3:269\u201375.","journal-title":"Biomed Rep"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-016-0337-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T08:23:58Z","timestamp":1567844638000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-016-0337-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["337"],"URL":"https:\/\/doi.org\/10.1007\/s12325-016-0337-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5]]}}}